| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.9 |
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.0086 | 0.9 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | selumetinib:BRD-A02303741 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.0091 | 0.9 |
| mRNA | serdemetan | FIMM | pan-cancer | AAC | 0.027 | 0.9 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | -0.0095 | 0.9 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | -0.0049 | 0.9 |